Articles related to TYPE 2 DIABETES

Older adults with diabetes and frailty frequently experience overtreatment despite individualized glycemic goals that prioritize safety over intensive control. A narrative review highlights deprescribing strategies, relaxed glycemic targets, and medication adjustments intended to reduce hypoglycemia, falls, and treatment burden.

Adults with type 2 diabetes initiating GLP-1 receptor agonists experienced higher rates of nonscarring alopecia than matched users of SGLT-2 or DPP-4 inhibitors. The association persisted across multiple analyses, though absolute risk remained low.

The ACC updated its expert consensus pathway for HFpEF, emphasizing diagnostic scoring, comorbidity assessment, and newer cardiometabolic therapies. The pathway reflects emerging evidence while remaining aligned with existing heart failure guidelines.

A Swedish register-based cohort associated GLP-1 receptor agonist use with higher relative risk of anterior ischemic optic neuropathy. Absolute event rates were low, and findings attenuated after diabetes-severity controls.

Nearly 89% of U.S. ischemic heart disease deaths in 2023 were attributable to modifiable risk factors, according to Global Burden of Disease data. Mortality rates declined substantially since 1990, although deaths linked to elevated BMI and fasting glucose increased.

A phase 2b trial found that biweekly bofanglutide significantly reduced HbA1c levels and produced weight loss in adults with type 2 diabetes. The findings add to ongoing development of longer-interval GLP-1 therapies, though larger and longer studies remain necessary.